Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Ensysce Biosciences, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 10 | 11 | +1 |
| Shares | 299.8K | 499.2K | +199.5K (+66.5%) |
| Value | $236.5K | $253.0K | +$16.5K (+7.0%) |
New holders (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 86,339 | $43.7K | 0.00% |
| XTX Topco Ltd | 13,236 | $6.70K | 0.00% |
| Virtu Financial LLC | 11,341 | $6.00K | 0.00% |
| Bank of America Corp | 62 | $31 | 0.00% |
Sold out (3)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| UBS Group AG | 12,610 | $9.96K |
| Renaissance Technologies LLC | 10,554 | $8.00K |
| Wells Fargo & Company | 25 | $20 |